SonoNeu
Palo Alto, California, United StatesSee on the map
SonoNeu is a General Inception spinout developing sonogenetics as a novel therapeutic modality. Its platform uses ultrasound to control engineered ion channels, aiming to enable non-invasive treatments.
- Open roles
- 1
- RaisedTotal raised
- $5.2M
- Investor
- 1
- Employees
- 2–10
reccy insights
SonoNeu’s clearest reported milestone is a $5.2 million grant announced on Apr 7, 2026, with the Advanced Research Projects Agency for Health identified as the lead funder. The funding supports the company’s work on sonogenetics, an approach that uses focused ultrasound to control engineered cells. SonoNeu describes its platform as drug-free and non-invasive, with potential applications that include peripheral and diabetic neuropathy; these are areas of intended development, not evidence of approved treatments or demonstrated clinical outcomes. The company’s founding team includes Venkat Reddy and Sreekanth Chalasani. The available employee range is 2–10, indicating a small team, but there is no specific hiring announcement or reported workforce change to highlight. Overall, the grant is a notable financing and research milestone, while public details on execution and clinical progress remain limited.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
Open roles1
What makes SonoNeu distinct
- 01Develops sonogenetics as a potential therapeutic modality.
- 02Uses focused ultrasound to control engineered cells.
- 03Targets engineered ion channels as part of its platform approach.
- 04Aims to enable non-invasive, drug-free therapeutic interventions.
Technology & products
- SonoNeu sonogenetics platform
A non-invasive platform using focused ultrasound to control engineered cells and ion channels, with potential therapeutic applications including peripheral and diabetic neuropathy.
- Sonogenetics platform using ultrasound to control engineered ion channels.
Research roots1
Labs and research groups this company came from or works with.
Funding
- GrantApr 2026$5.2MLed by Advanced Research Projects Agency for Health
Investors1
About SonoNeu
- Products
- SonoNeu sonogenetics platform
- Leadership
- Venkat ReddySreekanth Chalasani
- Focus areas
- Biotechnology, therapeutics, sonogenetics, focused ultrasound, engineered ion channels, neuropathy
- Headquarters
- Palo Alto, California, United States
- Employees
- 2–10